Hema

HEMA Biologics is a privately held U.S. biopharmaceutical company focused on rare bleeding disorders, especially hemophilia A and B patients with inhibitors. The company commercializes SEVENFACT, a recombinant activated factor VII product approved in the United States for treatment and control of bleeding episodes in adolescents and adults with hemophilia A or B with inhibitors. HEMA Biologics is also pursuing additional clinical development of eptacog beta for surgical use and related bleeding settings. The company positions itself as a specialized rare-disease organization combining commercialization, medical affairs, patient support, and clinical development in hematology.